Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Использование розувастатина в лечении больных группы риска сосудистых осложнений атеросклероза - Журнал Системные Гипертензии Том 8, №1
Использование розувастатина в лечении больных группы риска сосудистых осложнений атеросклероза
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Настоящий обзор посвящен новым данным, касающимся действия розувастатина у больных с высоким риском сердечно-сосудистых осложнений. Рассматриваются нелипидные аспекты действия препарата, влияние на уровень С-реактивного белка и взаимосвязь этого влияния с улучшением прогноза у разных групп больных. Приводятся сведения об антитромботическом действии препарата и данные сопоставления с другими статинами.
Ключевые слова: розувастатин, С-реактивный белок, многоцентровые исследования, антитромботическое действие статинов, профилактика сердечно-сосудистых заболеваний.
Key words: rosuvastatin, C-reactive protein, multicenter studies, antithrombotic activity of statins, prevention of cardiovascular diseases.
Ключевые слова: розувастатин, С-реактивный белок, многоцентровые исследования, антитромботическое действие статинов, профилактика сердечно-сосудистых заболеваний.
________________________________________________
Key words: rosuvastatin, C-reactive protein, multicenter studies, antithrombotic activity of statins, prevention of cardiovascular diseases.
Полный текст
Список литературы
1. Parka J-K, Mervaala EM, Muller DN et al. Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion. J Hypertens 2009; 27: 599–605.
2. Cormack-Aboud FC, Brinkkoetter PT, Pippin JW et al. Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant 2009; 24: 404–12.
3. Meijer P, Oyen WJG, Dekker D et.al. Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo. A New Perspective on Cardiovascular Protection. Arterioscler. Thromb Vasc Biol 2009; 29: 963–8.
4. Choi EY, Chang W, Lim S, Song BW et al. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh. Eur J Pharmacol 2010; 627 (1–3): 56–62.
5. Folkeringa RJ, de Vos C, Pinto YM et al. No effect of rosuvastatin on left ventricular hypertrophy in patients with hypertension. A prospective randomized open-label study with blinded endpoint assessment. Int J Cardiol 2010; 145 (1): 156–8.
6. Jialal I, Devaraj S, Venugopal SK. C-Reactive protein: risk marker or mediator in atherothrombosis? Hypertens 2004; 4 (1): 6–11.
7. Ridker PM, Rifai N, Pfeffer A et al. Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels. Circulation 1998; 98: 839–44.
8. Mannacio VA, Iorio D, Amicis V et al. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: A randomized trial. J Thorac Cardiovasc Surg 2008; 136: 1541–8.
9. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006; 13 (3): 123–9.
10. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
11. Cleland JGF, McMurray JJV, Kjekshus J et al. Wikstrand, on behalf of the CORONA Study Group. Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin. A Report From CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009; 54; 1850–9.
12. McMurray JJV, Kjekshus J, Gullestad L et al. Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). A Retrospective Analysis. Circulation 2009; 120: 2188–96.
13. Bonetti PO, Lerman LO, Napoli C. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003; 24: 225–48.
14. Heeschen С, Hamm CW, Laufs U et al. Withdrawal of statins increases event rats in patients with acute coronary syndromes. Circulation 2002; 105: 1446–52.
15. Glynn RJ, Danielson E, Fonsecaet FAH et al. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N Engl J Med 2009; 360: 1851–61.
16. Ridker PM, Danielson E, Fonseca FA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373 (9670): 1175–82.
17. Michos ED, Blumenthal RS. Prevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S.: Implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) Study. J Am Coll Cardiol 2009; 53: 931–5.
2. Cormack-Aboud FC, Brinkkoetter PT, Pippin JW et al. Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant 2009; 24: 404–12.
3. Meijer P, Oyen WJG, Dekker D et.al. Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo. A New Perspective on Cardiovascular Protection. Arterioscler. Thromb Vasc Biol 2009; 29: 963–8.
4. Choi EY, Chang W, Lim S, Song BW et al. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh. Eur J Pharmacol 2010; 627 (1–3): 56–62.
5. Folkeringa RJ, de Vos C, Pinto YM et al. No effect of rosuvastatin on left ventricular hypertrophy in patients with hypertension. A prospective randomized open-label study with blinded endpoint assessment. Int J Cardiol 2010; 145 (1): 156–8.
6. Jialal I, Devaraj S, Venugopal SK. C-Reactive protein: risk marker or mediator in atherothrombosis? Hypertens 2004; 4 (1): 6–11.
7. Ridker PM, Rifai N, Pfeffer A et al. Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels. Circulation 1998; 98: 839–44.
8. Mannacio VA, Iorio D, Amicis V et al. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: A randomized trial. J Thorac Cardiovasc Surg 2008; 136: 1541–8.
9. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006; 13 (3): 123–9.
10. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
11. Cleland JGF, McMurray JJV, Kjekshus J et al. Wikstrand, on behalf of the CORONA Study Group. Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin. A Report From CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009; 54; 1850–9.
12. McMurray JJV, Kjekshus J, Gullestad L et al. Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). A Retrospective Analysis. Circulation 2009; 120: 2188–96.
13. Bonetti PO, Lerman LO, Napoli C. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003; 24: 225–48.
14. Heeschen С, Hamm CW, Laufs U et al. Withdrawal of statins increases event rats in patients with acute coronary syndromes. Circulation 2002; 105: 1446–52.
15. Glynn RJ, Danielson E, Fonsecaet FAH et al. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N Engl J Med 2009; 360: 1851–61.
16. Ridker PM, Danielson E, Fonseca FA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373 (9670): 1175–82.
17. Michos ED, Blumenthal RS. Prevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S.: Implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) Study. J Am Coll Cardiol 2009; 53: 931–5.
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.